产品说明书

Tacrolimus monohydrate

Print
Chemical Structure| 109581-93-3 同义名 : 他克莫司一水合物 ;FK506 monohydrate;FR900506 monohydrate;Fujimycin monohydrate
CAS号 : 109581-93-3
货号 : A377737
分子式 : C44H71NO13
纯度 : 98%
分子量 : 822.034
MDL号 : -
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(127.73 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase. This inhibition leads to the suppression of T-lymphocyte signal transduction and IL-2 transcription, conferring immunosuppressive properties [1].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01028716 Acute Biphenotypic Leukemia ... 展开 >> Acute Erythroid Leukemia in Remission Acute Leukemia in Remission Acute Megakaryoblastic Leukemia Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia in Remission Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With Multilineage Dysplasia Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 Acute Undifferentiated Leukemia Adult Acute Lymphoblastic Leukemia in Complete Remission B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Burkitt Lymphoma Childhood Acute Lymphoblastic Leukemia in Complete Remission DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma Myelodysplastic Syndrome Recurrent Anaplastic Large Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Secondary Acute Myeloid Leukemia T Lymphoblastic Lymphoma 收起 << Phase 2 Recruiting - United States, Washington ... 展开 >> VA Puget Sound Health Care System Not yet recruiting Seattle, Washington, United States, 98101 Contact: Thomas Chauncey    206-764-2969    thomas.chauncey@va.gov    Principal Investigator: Thomas Chauncey          Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit    206-667-1317    rsalit@fredhutch.org    Principal Investigator: Rachel B. Salit 收起 <<
NCT03602898 Acute Lymphoblastic Leukemia i... 展开 >>n Remission Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Acute Myeloid Leukemia in Remission Blasts 5 Percent or Less of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Donor Minimal Residual Disease Myelodysplastic Syndrome Myelofibrosis Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia 收起 << Phase 2 Not yet recruiting September 17, 2023 United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Masumi Ueda    206-667-4546       Principal Investigator: Masumi Ueda 收起 <<
NCT00589316 Acute Myeloid Leukemia Arising... 展开 >> From Previous Myelodysplastic Syndrome Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission CD45-Positive Neoplastic Cells Present Chronic Myelomonocytic Leukemia Previously Treated Myelodysplastic Syndrome Refractory Anemia With Excess Blasts Refractory Anemia With Ring Sideroblasts Refractory Cytopenia With Multilineage Dysplasia Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts 收起 << Phase 1 Active, not recruiting October 1, 2024 United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.22mL

0.24mL

0.12mL

6.08mL

1.22mL

0.61mL

12.16mL

2.43mL

1.22mL
参考文献

[1]Thomson AW, et al. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.

[2]Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016 Nov;39(6):877-886.

[3]Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α expression in vivo. Mol Med Rep. 2014 Aug;10(2):585-92.